Patents by Inventor Adnan M. M. Mjalli

Adnan M. M. Mjalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Naphthalenedione nitric oxide synthase (NOS) inhibitors
    Patent number: 5866569
    Abstract: There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the formula I:. when R.sub.2 is H then R.sub.1 is selected from the group consisting of:1) aryl,--NH--C.sub.0 -C.sub.10 alkyl -aryl, N-(C.sub.0 -C.sub.10 alkyl substituted aryl).sub.2, --C.sub.0 -C.sub.10 alkyl substituted aryl, --N(C.sub.0 -C.sub.10 alkyl substituted aryl)(C.sub.0 -C.sub.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: February 2, 1999
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Sepehar Sarshar, Chengzhi Zhang
  • Imidazole derivatives as MDR modulators
    Patent number: 5840721
    Abstract: The present invention relates to polysubsituted imidazole having formula 1 ##STR1## These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: November 24, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Chengzhi Zhang
  • Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
    Patent number: 5770620
    Abstract: The present invention provides novel protein tyrosine phosphatase modulating compounds having an aryl acrylic acid structure, compositions comprising the compounds, and methods of making and using the same.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: June 23, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Xiaodong Cao, Edmund J. Moran
  • Imidazole derivatives useful as modulators of multi drug resistances
    Patent number: 5756527
    Abstract: The present invention relates to imidazole derivatives having formula 1 ##STR1## wherein: R.sub.1 is selected from the group consisting of: mono-,di-,and tri-substituted phenyl or thienyl, the substituents are selected from the group consisting of:(i) substituted C.sub.1-6 alkyl, substituted C.sub.2-6 alkyloxy, wherein the substituents are selected from the group consisting of hydrogen or C.sub.1-6 alkoxy;(ii) C.sub.1-11 CO.sub.2 R.sub.5, trans-CH.dbd.CHCO.sub.2 R.sub.5, wherein R.sub.5 is C.sub.1-11 alkyl, or phenyl C.sub.1-11 alkyl;R.sub.2 and R.sub.3 are mono-, di, and tri-substituted phenyl wherein the substituents are independently selected from:(i) halo;(ii) C.sub.1-6 alkyl-amino, or di(C.sub.1-6 alkyl)amino, and R.sub.4 is hydrogen.These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: May 26, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Sepehr Sarshar
  • Nitric oxide synthase (NOS) inhibitors
    Patent number: 5723451
    Abstract: There are disclosed methods useful for the inhibition of inducible nitric oxide synthase by the adminstration of a compound of the Formula I: ##STR1## to a patient in need of such inhibition such as hypotension, inflammation, autoimmune diseases and septic shock and the like.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: March 3, 1998
    Assignee: Ontogen Corporation
    Inventors: Adnan M. M. Mjalli, Sepehar Sarshar, Chengzhi Zhang